Should I Buy IMNN? IMNN 2026 Analysis

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.310

1 Day change

-2.65%

52 Week Range

41.220

Analysis Updated At

2026/01/29

Imunon Inc (IMNN) is not a good buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, and the company's financial performance is weak with declining net income and EPS. There are no significant positive catalysts, no recent news, and no strong trading signals to suggest a compelling entry point.

Technical Analysis

The stock is in a bearish trend with MACD below zero and negatively expanding. RSI is neutral at 30.135, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.563, with key support at 3.33 and resistance at 3.797.

Options Data

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Weak financial performance with a 29.23% YoY drop in net income and a 76.94% YoY drop in EPS. No positive trading signals or recent news to support the stock.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped by 29.23% YoY to -$3,429,124, and EPS declined by 76.94% YoY to -1.01. Gross margin remained at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data on analyst ratings or price target changes available.

1 Analyst Rating

Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.400

Low

Averages

High

Current: 3.400

Low

Averages

High

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

AI Analysis

2025-05-19

Reason

D. Boral Capital

Jason Kolbert

Price Target

AI Analysis

2025-05-19

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Imunon to Hold from Buy without a price target. The company announced "encouraging" six-month follow-up data from its Phase 1 COVID-19 vaccine study, but the update is immaterial to the investment thesis, which remains centered on Imunon's ovarian cancer program, the analyst tells investors in a research note. The firm says the "more pressing development" is the recently filed prospectus for potentially dilutive financing that could create a significant number of new shares. Given the scale of dilution and uncertainty around shareholder approval, D. Boral downgraded the stock.

Boral Capital

D. Boral

Buy

downgrade

$29 -> $17

2025-05-13

Reason

Boral Capital

D. Boral

Price Target

$29 -> $17

2025-05-13

downgrade

Buy

Reason

D. Boral Capital lowered the firm's price target on Imunon to $17 from $29 and keeps a Buy rating on the shares. The firm now anticipates a series of dilutive financings that are likely to exceed its prior expectations. Imunon has entered a pivotal new phase in its development with the initiation of the Phase 3 OVATION 3 trial evaluating IMNN-001, its lead DNA-based immunotherapy candidate, in newly diagnosed advanced ovarian cancer, the analyst tells investors in a research note. With only $2.9M in cash as of March 31, the company's "financial position remains precarious," contends D. Boral.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNN

Unlock Now

IMNN Should I Buy

IMNN Should I Buy

Should You Buy Imunon Inc (IMNN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch